Nextgen Cure

NextGen Cure is a biotechnology company dedicated to the discovery and development of first-in-class therapeutics targeting the NF-κB pathway. Founded on research from Singapore's Agency for Science, Technology and Research (A*STAR), the company focuses on highly specific modulation of NF-κB to treat cancer and inflammatory diseases without the systemic toxicity associated with broad inhibitors. Their pipeline includes peptide-based and small molecule candidates for indications such as glioblastoma and hepatocellular carcinoma. The company's approach emphasizes precision targeting of protein-protein interactions within the NF-κB complex. NextGen Cure aims to translate cutting-edge molecular biology into transformative treatments for patients with high unmet medical needs.